Eterna Therapeutics Inc. (NASDAQ:ERNA) Sees Large Drop in Short Interest

Eterna Therapeutics Inc. (NASDAQ:ERNA) was the target of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 186,600 shares, a decrease of 39.6% from the January 31st total of 309,100 shares. Based on an average trading volume of 10,530,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.5% of the shares of the company are short sold.

Eterna Therapeutics Price Performance

ERNA traded up $0.01 on Tuesday, hitting $0.29. 206,868 shares of the stock were exchanged, compared to its average volume of 15,572,489. Eterna Therapeutics has a 12 month low of $0.22 and a 12 month high of $2.63. The business has a 50-day moving average of $0.35 and a two-hundred day moving average of $0.79. The firm has a market capitalization of $1.55 million, a price-to-earnings ratio of -0.03 and a beta of 4.29.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Eterna Therapeutics stock. Geode Capital Management LLC boosted its stake in Eterna Therapeutics Inc. (NASDAQ:ERNA) by 1,159.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 257,310 shares of the company’s stock after purchasing an additional 236,875 shares during the period. Geode Capital Management LLC owned about 4.76% of Eterna Therapeutics worth $76,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 70.55% of the company’s stock.

Eterna Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.